Read by QxMD icon Read


shared collection
33 papers 100 to 500 followers
Arman Qamar, Deepak L Bhatt
No abstract text is available yet for this article.
April 12, 2016: Circulation
Meagan M Wasfy, Aaron L Baggish
No abstract text is available yet for this article.
May 17, 2016: Circulation
Matthew Nayor, Ramachandran S Vasan
The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guideline advocated several changes from the previous Adult Treatment Panel III guidelines. Assuming full implementation, the 2013 ACC/AHA guideline would identify ≈13 million Americans as newly eligible for consideration of statin therapy. Three features of the 2013 ACC/AHA guideline primarily responsible for these differences are the specific risk assessment tool endorsed, the risk threshold considered sufficient to warrant primary prevention statin therapy, and the decision not to include cholesterol treatment targets...
May 3, 2016: Circulation
Naoki Okumura, Pardeep S Jhund, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Karl Swedberg, Michael R Zile, Scott D Solomon, Milton Packer, John J V McMurray
BACKGROUND: Many episodes of worsening of heart failure (HF) are treated by increasing oral therapy or temporary intravenous treatment in the community or emergency department (ED), without hospital admission. We studied the frequency and prognostic importance of these episodes of worsening in the Prospective Comparison of ARNI (angiotensin-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)...
June 7, 2016: Circulation
Akshay Bagai, Deepak L Bhatt, John W Eikelboom, G B John Mancini, Eric A Cohen, Ram Vijayaraghavan, Asim N Cheema, Jacob A Udell, Joel Niznick, Jean-Francois Tanguay, Subodh Verma, Shamir R Mehta
No abstract text is available yet for this article.
May 24, 2016: Circulation
Asif Machhada, Alexander V Gourine, Gareth L Ackland
No abstract text is available yet for this article.
August 25, 2015: Journal of the American College of Cardiology
Nikolaus Sarafoff, Robert A Byrne, Julinda Mehilli, Dirk Sibbing, Steen D Kristensen, Karl-Ludwig Laugwitz, Michael Maeng, Adnan Kastrati
No abstract text is available yet for this article.
September 1, 2015: Journal of the American College of Cardiology
Femi Philip
No abstract text is available yet for this article.
September 1, 2015: Journal of the American College of Cardiology
Giuseppe Licata, Pietro Di Pasquale, Gaspare Parrinello, Antonietta Cardinale, Angela Scandurra, Giuseppe Follone, Christiano Argano, Antonino Tuttolomondo, Salvatore Paterna
BACKGROUND: Diuretics have been accepted as first-line treatment in refractory congestive heart failure (CHF), but a lack of response to them is a frequent event. A randomized, single-blind study was performed to evaluate the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) infusion in the treatment of refractory New York Heart Association (NYHA) class IV CHF and a normosodic diet during follow-up. Materials and Methods One hundred seven patients (39 women and 68 men, age range 65-90 years) with refractory CHF (NYHA class IV) of different etiologies, who were unresponsive to high oral doses of furosemide, angiotensin-converting enzyme inhibitors, digitalis, and nitrates, were enrolled...
March 2003: American Heart Journal
Gillian M Keating
Cangrelor (Kengrexal(®), Kengreal(™)) is an intravenously administered P2Y12 receptor inhibitor. It is direct-acting and reversible, with a very rapid onset and offset of action. The randomized, double-blind, multinational, phase III CHAMPION PHOENIX trial compared the efficacy of intravenous cangrelor with that of oral clopidogrel in patients requiring percutaneous coronary intervention (PCI) for stable angina pectoris, a non-ST-segment elevation acute coronary syndrome or ST-segment elevation myocardial infarction (MI)...
August 2015: Drugs
Justin Fongemie, Erika Felix-Getzik
Nebivolol is a highly selective β1-adrenergic receptor antagonist with a pharmacologic profile that differs from those of other drugs in its class. In addition to cardioselectivity mediated via β1 receptor blockade, nebivolol induces nitric oxide-mediated vasodilation by stimulating endothelial nitric oxide synthase via β3 agonism. This vasodilatory mechanism is distinct from those of other vasodilatory β-blockers (carvedilol, labetalol), which are mediated via α-adrenergic receptor blockade. Nebivolol is approved for the treatment of hypertension in the US, and for hypertension and heart failure in Europe...
August 2015: Drugs
Lisa Hauk
No abstract text is available yet for this article.
July 15, 2015: American Family Physician
Richard Kones, Umme Rumana
Since their introduction, statin (HMG-CoA reductase inhibitor) drugs have advanced the practice of cardiology to unparalleled levels. Even so, coronary heart disease (CHD) still remains the leading cause of death in developed countries, and is predicted to soon dominate the causes of global mortality and disability as well. The currently available non-statin drugs have had limited success in reversing the burden of heart disease, but new information suggests they have roles in sizeable subpopulations of those affected...
July 2015: Drugs
Bruno Levy, Olivier Bastien, Bendjelid Karim, Karim Benjelid, Alain Cariou, Tahar Chouihed, Alain Combes, Alexandre Mebazaa, Bruno Megarbane, Patrick Plaisance, Alexandre Ouattara, Christian Spaulding, Christian Splaulding, Jean-Louis Teboul, Fabrice Vanhuyse, Thierry Boulain, Kaldoun Kuteifan
Unlike for septic shock, there are no specific international recommendations regarding the management of cardiogenic shock (CS) in critically ill patients. We present herein recommendations for the management of cardiogenic shock in adults, developed with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system by an expert group of the French-Language Society of Intensive Care (Société de Réanimation de Langue Française (SRLF)), with the participation the French Society of Anesthesia and Intensive Care (SFAR), the French Cardiology Society (SFC), the French Emergency Medicine Society (SFMU), and the French Society of Thoracic and Cardiovascular Surgery (SFCTCV)...
December 2015: Annals of Intensive Care
Henrik Vadmann, Peter Brønnum Nielsen, Søren Pihlkjær Hjortshøj, Sam Riahi, Lars Hvilsted Rasmussen, Gregory Y H Lip, Torben Bjerregaard Larsen
Atrial flutter confers a thromboembolic risk, but contrary to atrial fibrillation the relationship has only been addressed in few studies. This study performs an up to date systematic review of the literature to investigate the association between atrial flutter and thromboembolic events. Articles were found by MEDLINE, EMBASE search and a manual search of references list in included articles. International guidelines, meta-analyses, reviews, case reports, studies reporting thromboembolic events in relation to ablation, or cardioversion procedures, echocardiography, and observational studies were found eligible in this review...
September 2015: Heart: Official Journal of the British Cardiac Society
Jennifer N Smith, Jenna M Negrelli, Megha B Manek, Emily M Hawes, Anthony J Viera
Acute coronary syndrome (ACS) describes the range of myocardial ischemic states that includes unstable angina, non-ST elevated myocardial infarction (MI), or ST-elevated MI. ACS is associated with substantial morbidity and mortality and places a large financial burden on the health care system. The diagnosis of ACS begins with a thorough clinical assessment of a patient's presenting symptoms, electrocardiogram, and cardiac troponin levels as well as a review of past medical history. Early risk stratification can assist clinicians in determining whether an early invasive management strategy or an initial conservative strategy should be pursued and can help determine appropriate pharmacologic therapies...
March 2015: Journal of the American Board of Family Medicine: JABFM
Martin M LeWinter
No abstract text is available yet for this article.
December 18, 2014: New England Journal of Medicine
C M Plymen, G S Carr-White, S Kapetanakis
No abstract text is available yet for this article.
December 16, 2014: BMJ: British Medical Journal
Sean P Collins, Alan B Storrow, Phillip D Levy, Nancy Albert, Javed Butler, Justin A Ezekowitz, G Michael Felker, Gregory J Fermann, Gregg C Fonarow, Michael M Givertz, Brian Hiestand, Judd E Hollander, David E Lanfear, Peter S Pang, W Frank Peacock, Douglas B Sawyer, John R Teerlink, Daniel J Lenihan
Heart failure (HF) afflicts nearly 6 million Americans, resulting in 1 million emergency department (ED) visits and over 1 million annual hospital discharges. The majority of inpatient admissions originate in the ED; thus, it is crucial that emergency physicians and other providers involved in early management understand the latest developments in diagnostic testing, therapeutics, and alternatives to hospitalization. This article discusses contemporary ED management as well as the necessary next steps for ED-based acute HF research...
January 2015: Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine
2015-08-17 16:50:48
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"